Cellular avidity for immuno-oncology research

The only integrated biomarker for immune cell discovery breakthroughs

Jump to:

What is cell avidity analysis?

A new approach that reveals the key step in the mode of action of immunotherapy products

Researchers are searching for the most effective immune cells against cancer using an array of in vitro assays and affinity measurements. However, these measurements do not provide reliable indicators for the performance of an immune product in vivo or in clinical. What seems to be the best candidate now, might turn out to be the wrong one later.

Cell avidity analysis measures the total intercellular strength between interacting cells and provides a new, integrated biomarker for immune cell functionality. This allows researchers to quickly and effectively identify and characterize the cell that recognises, binds to, and ultimately attacks tumor cells.

Transforming drug discovery process of immunotherapies​

Cell avidity measurements can unlock faster R&D cycles and rational drug design

While in vitro functional assays are used today as the status quo for narrowing down IO candidates, they are time-consuming and suboptimal predictors of the efficacy of the immune products in mouse or clinical studies. This leads to long development cycles that include multiple rounds of mouse studies that require several months. 

Cell avidity analysis allows to directly optimize cellular binding and interaction of immunotherapy products at an early stage. Ultimately, these measurements enable more efficient rational drug design, leading to better candidate selection and faster drug development by reducing the number of mouse studies needed.​

Explore the research applications

CAR T cells

Select optimally-functioning CAR T cells based on their avidity and fine-tune the desired avidities to avoid on-target/off-tumor binding.

TCR T cells

Improve the functional correlation of TCR T cells by replacing affinity measurements with avidity. Reveal TCR modified T cells with optimal avidity that improve T cell responses.

Cell engagers

Test the binding avidity associated with different BsAb and compare the avidity of T cells engaged by these BsAb to find the most desirable response.

CAR-NK / NK cells

Compare the avidity of NK or CAR-NK cells from different donors and correlate the respective outcomes to effector cell functionalities, such as cell killing.

LUMICKS empowers researchers

Customer insights

Unlocking experiments in a whole new dimension

Our solution

z-Movi®

Cell Avidity Analyzer

The z-Movi is a unique instrument that enables you to identify the most potent effector cell populations, by measuring the overall binding strength – or avidity – between effector and target cells. Get avidity data from hundreds of individual cells in a matter of minutes. 

Discover the z-Movi